To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients
NCT ID: NCT05856487
Last Updated: 2024-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
228 participants
INTERVENTIONAL
2023-06-30
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation
NCT03950843
Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD)
NCT04882228
A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention
NCT04848220
Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD
NCT04521452
SB-480848 In Subjects With Coronary Heart Disease
NCT00269048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NVP-2203
NVP-2203 Plus other Placebo for up to 8 weeks, oral dose
NVP-2203
Take it once daily for 8 weeks orally.
NVP-2203-R1 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R2 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R3 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R1
NVP-2203-R1 Plus other Placebo for up to 8 weeks, oral dose
NVP-2203-R1
Take it once daily for 8 weeks orally.
NVP-2203 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R2 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R2
NVP-2203-R2 Plus other Placebo for up to 8 weeks, oral dose
NVP-2203-R2
Take it once daily for 8 weeks orally.
NVP-2203 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R1 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R3 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R3
NVP-2203-R3 Plus other Placebo for up to 8 weeks, oral dose
NVP-2203-R3
Take it once daily for 8 weeks orally.
NVP-2203 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R1 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R2 Placebo
Take it once daily for 8 weeks orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NVP-2203
Take it once daily for 8 weeks orally.
NVP-2203-R1
Take it once daily for 8 weeks orally.
NVP-2203-R2
Take it once daily for 8 weeks orally.
NVP-2203-R3
Take it once daily for 8 weeks orally.
NVP-2203 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R1 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R2 Placebo
Take it once daily for 8 weeks orally.
NVP-2203-R3 Placebo
Take it once daily for 8 weeks orally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary hypercholesterolemia
* Subjects who have ability to comprehend the contents of study and before participating in trial and have willingness to sign of informed consent in writing
Exclusion Criteria
* Patients who were diagnosed with a malignant tumor within five years before Visit
* Inadequate subject for the clinical trial by the investigator's decision
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NVP Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
SH Lee, MD
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NVPhealthcare
Suwon, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NVP-2203_P3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.